Market revenue in 2023 | USD 167.4 million |
Market revenue in 2030 | USD 425.3 million |
Growth rate | 14.3% (CAGR from 2023 to 2030) |
Largest segment | Phase ii |
Fastest growing segment | Phase III |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 49.88% in 2023. Horizon Databook has segmented the Mexico cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico is an attractive destination for outsourcing the cell and gene therapy clinical trials as cost plays a major factor. Moreover, the proximity to the U.S. and the availability of investigators in urban areas also help in cost-cutting. As the population here cannot afford treatment of chronic diseases, they usually prefer participating in such trials. Hence, availability of diverse patient pool is one of the drivers.
The establishment of regulatory entity, the Federal Commission for the Protection against Sanitary Risk (COFEPRIS), and shortening the set up time for cell and gene therapy clinical trials to two months has also attracted many clients. In addition to all this, there is a huge investment for infrastructure development to provide better facilities.
Mexico’s largest hospital chain has invested around USD 700 million to build 15 new hospitals to encourage cell and gene therapy clinical trials and medical tourism. Mexico is also one of the preferred countries in Latin America due to cost saving and speed with which the trials are performed. The increasing number of trials outsourced to this country has also brought about many regulatory changes favoring growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico cell and gene therapy clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Mexico cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account